DFINE Enrolls First Patient in STAR Tumor Ablation System Clinical Trial

DFINE announced that the first patient has been enrolled in the EU-STAR Clinical Trial, to evaluate clinical outcomes in patients receiving treatment with the STAR Tumor Ablation System for the palliative treatment of metastatic spinal tumors.

Advertisement

The multi-center trial is the first prospective study to evaluate the efficacy of the STAR Tumor Ablation System. It will include 40 patients at five centers across Germany and France.

 

DFINE is a privately held company and focuses on providing solutions for the minimally invasive treatment of spinal diseases.

More Articles on Spine:

Hospital for Special Surgery Names Dr. Todd Albert Surgeon-in-Chief
Costs for SI Joint Disruption, Sacroiliitis About $270M Over 5 Years
The Robotic Difference: How New Technology Could Impact Spine

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spine

Advertisement

Comments are closed.